Itraconazol Actavis

Itraconazole, the active ingredient in Itraconazol Actavis, is a triazole antifungal presented as an oral formulation for oral use. It treats systemic fungal infections such as blastomycosis, histoplasmosis, aspergillosis, candidiasis, dermatophytosis and sporotrichosis in adults and children when indicated, and is used for both invasive and superficial mycoses under medical supervision.

GNH USA supplies Itraconazol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global healthcare providers.

Itraconazole is employed to treat a variety of systemic and superficial fungal infections. - Blastomycosis: eradicates the causative fungus and resolves pulmonary and disseminated disease. - Histoplasmosis: clears infection in acute and chronic forms, including disseminated cases. - Aspergillosis: controls invasive disease and chronic pulmonary infection. - Candidiasis (oropharyngeal and esophageal): eliminates Candida overgrowth and promotes mucosal healing. - Dermatophytosis: treats skin infections caused by dermatophytes. - Sporotrichosis: resolves subcutaneous infection and prevents spread.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Diarrhea: loose stools occurring during therapy. - Rash: skin redness or itching. - Taste disturbance: altered perception of flavors.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac failure: worsening of pre‑existing heart conditions. - Visual disturbances: blurred vision or photophobia. - Severe liver injury: hepatic failure requiring medical attention. - Anaphylaxis: rare allergic reaction with airway compromise.

Itraconazole requires careful monitoring due to its pharmacologic profile. - Liver function monitoring: assess hepatic enzymes before and during treatment. - Drug interaction vigilance: avoid concomitant strong CYP3A4 inhibitors. - Pregnancy risk: classified as Category D; use only if benefits outweigh risks. - Hypersensitivity avoidance: discontinue if allergic reactions occur. - Cardiac assessment: monitor patients with existing heart failure. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Itraconazole has notable interactions that may require dose adjustment or avoidance. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase itraconazole levels. - Certain statins (e.g., simvastatin): risk of myopathy. - Antiarrhythmic quinidine: can cause cardiac toxicity. - HIV protease inhibitors: elevate itraconazole exposure. - Macrolide antibiotics (e.g., erythromycin): may raise drug concentrations. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Oral contraceptives: decreased hormonal effectiveness. - Warfarin: potential alteration of anticoagulant effect. - Digoxin: possible increased serum levels. - Antacids: may impair absorption if taken simultaneously.